141 216

Cited 0 times in

이상지질혈증 치료 약제의 최신지견

Other Titles
 Update on the Pharmacologic Agents for Dyslipidemia 
Authors
 이상학 
Citation
 Journal of Korean Diabetes, Vol.16(4) : 269-275, 2015 
Journal Title
 Journal of Korean Diabetes 
ISSN
 2233-7431 
Issue Date
2015
Keywords
Cholesterol ester transfer proteins ; Ezetimibe ; Fibric acids ; Human PCSK9 protein ; Hydroxymethylglutaryl-CoA reductase inhibitors ; Niacin ; Omega-3 fatty acids
Abstract
Although statins have demonstrated consistent and strong effects on cardiovascular prevention, non-statin drugs have failed to show additional clinical benefit. Consequently, statins are currently recommended as first-line therapy in dyslipidemia. On the contrary, non-statin drugs are indicated in limited cases in which statins are not sufficiently effective or intolerable. A recent trial on ezetimibe provides evidence supporting further prescription of this agent. Proprotein convertase subtilisin-kexin type 9 inhibitors have strong low-density lipoprotein-cholesterol-lowering effects and were just approved in Western countries. However, results of clinical outcomes are not yet available. Other non-statin lipid-modifying agents have their own roles and limitations. Thus, it is important to have correct knowledge on these agents for optimal treatment of dyslipidemic patients.
Files in This Item:
T201505437.pdf Download
DOI
10.4093/jkd.2015.16.4.269
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Lee, Sang Hak(이상학) ORCID logo https://orcid.org/0000-0002-4535-3745
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/157097
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links